ELI LILLY AND CO.
-
USD
(-)
- Temps différé 15min - Actions NYSE
| Ouverture: | - |
| Variation: | - |
| Volume: | - |
| + Bas: | - |
| + Haut: | - |
| Ecart + Bas / + Haut: | - |
| Type: | Actions |
| Ticker: | LLY |
| ISIN: |
Actualités et vidéos ELI LILLY AND CO.
Pour plus d'actualités, utilisez notre fonction de recherche avancée.
ELI LILLY AND CO. - Plus d'actualités...
ELI LILLY AND CO. - Plus d'actualités...
- TRULICITY® (dulaglutide) est indiqué comme traitement d’appoint à un régime alimentaire, à l’exercice et au traitement standard pour réduire le risque d’accident vasculaire cérébral non mortel chez les adultes atteints de diabète de type 2 qui présentent des facteurs de risque cardiovasculaires multiples ou une maladie cardiovasculaire établie
- Lilly dévoile des données de validation de principe concernant l’anticorps neutralisant LY-CoV555 pour le traitement de la COVID-19 en contexte ambulatoire
- Correction d'un communiqué du 23.10.2019, 17:55 CET/CEST - Eli Lilly and Company: Q319LillySalesandEarningsPressRelease
- Eli Lilly and Company: Q319LillySalesandEarningsPressRelease
- Eli Lilly and Company: Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance
- Eli Lilly and Company: Files Form 3 and 4
- Eli Lilly and Company: Lilly Announces Voluntary Delisting from Euronext Paris
- Eli Lilly and Company: Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance
- Eli Lilly and Company: Lilly Declares Third-Quarter 2019 Dividend
- Eli Lilly and Company: Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health
- Eli Lilly and Company: Eli Lilly and Company Announces Plan for Divestiture of its Remaining Interest in Elanco Animal Health
- Eli Lilly and Company: Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology
- Eli Lilly and Company: Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting
- Eli Lilly and Company: Lilly Announces 15 Percent Dividend Increase
- Eli Lilly and Company: Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance
- Elanco Preliminary Prospectus
- ELI LILLY AND COMPANY FILES FORM 10-Q
- ELI LILLY AND COMPANY FILES FORM 3 and FORM 4
- ELI LILLY AND COMPANY FILES A FORM 8-K
- Lilly to Separate Elanco Animal Health with Initial Public Offering
- Eli Lilly and Company: Lilly Completes Acquisition of ARMO BioSciences
- Lilly Declares Third-Quarter 2018 Dividend
- Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
- Eli Lilly and Company: FDA Approves OLUMIANT(R) (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
